Replies to post #705 on Abbvie Inc (ABBV)

[DewDiligence]

ABBV 1Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/04/30/abbvie-abbv-q1-2022-earnings-call-transcript/

[DewDiligence]

ABBV 2Q22 results:

https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-second-quarter-2022-financial-results

2022 non-GAAP EPS guidance is unchanged at $13.78-13.98, including a $0.23 charge for in-process R&D during 1H22, but no IPR&D charge relating to 2H22 insofar as M&A activity during 1H22 is not yet known

ABBV set aside $2B to settle opioid litigation (https://finance.yahoo.com/news/1-abbvie-sets-aside-2-121111751.html ), but this charge is excluded from the non-GAAP results are guidance.